As we reported last November, the NOR-SWITCH Phase IV study concluded that patients could be safely and effectively switched from originator infliximab (Remicade®) to Celltrion’s biosimilar product CT-P13 (Remsima®).

On February 17, Celltrion Healthcare and Pfizer released primary outcome data at the 12th Congress of the European Crohn’s and Colitis Organisation (ECCO) for Remsima®.  The Phase III randomized clinical trial in 220 patients with Crohn’s disease used the Crohn’s Disease Activity Index (CDAI) to quantify symptoms in these patients. According to the press release, over 6-week and 30-week time periods, CT-P13 demonstrated similar clinical remission to reference infliximab treatment groups.

Stay tuned for updates from Big Molecule Watch.